Eurofins CDMOis a leading global Contract Development and Manufacturing Organization (CDMO) that provides clients with Active Pharmaceutical Ingredients (APIs) / Drug Substance and Drug Product development for biologicals and small molecules. Science is our foundation and allows us to support small and major biopharmaceutical companies. Our sustainable and flexible methods help them achieve their pre-clinical and clinical milestones on time.

Our service 

Drug Substance/API development

Solid State Research & Development

Pre-Formulation, Formulation Development

Analytical Development

Sterile GMP Manufacturing

Non-Sterile GMP Manufacturing

Clinical packaging and logistics

Project management

CMC RA

We are experts in breakthrough technologies for APIs / Drug Substance and Drug Product development, highly potent compoundspoorly soluble drugs, lyophilization processes and specific therapeutic areas (immunotherapies, orphan drugs, pediatric dosage forms, etc.)

CDMO Services

Hover the images to learn more

Click on the images to learn more

Pre-Clinical Services

Learn more

Small Molecules - API Development & Manufacturing

Learn more

Small Molecules - DP Development & Manufacturing

Learn more

Biologics - DS/DP Development & Manufacturing

Learn more

CDMO Services

Hover the images to learn more

DP Sterile Manufacturing

Learn more

DP Non-Sterile Manufacturing

Learn more

Clinical Trial Material, Packaging & Logistics

Learn more

Regulatory Services

Learn more

Choose Eurofins CDMO to help you:

  • Move rapidly through the drug development value chain (API/DS and DP)
  • Perform complex formulation screening and development
  • Accelerate process development and scale-up under GMP compliance
  • Achieve clinical & small commercial manufacturing batches (Sterile and Non Sterile)
  • Provide clinical trial material including packaging and logistics
  • Ensure regulatory compliance throughout each stage of the development cycle with full CMC-RA support
Go to article: Home | The path of yeast resistanceGo to article: NSFGo to article: EditorialGo to article: ContentsGo to article: NewsGo to article: Emirates SkyCargoGo to article: The pharma industry briefingGo to article: A resolution for the new decade: resolve the US opioid crisisGo to article: Eurofins CDMOGo to article: Precision medicine: what barriers remain?Go to article: Can recyclable packaging turn the pharma industry green?Go to article: Phoenix Company InsightGo to article: PhoenixGo to article: Vertex’s Trikafta: treating the genetic basis of cystic fibrosis Go to article: Accurate Biometrics Company Insight Go to article: Accurate BiometricsGo to article: Q&A: talking innovation with the Association for the Cannabinoid IndustryGo to article: Yeast of burden: how to develop better antifungal drugsGo to article: Loose lips bring risks: protecting pharma against leaks and fraud Go to article: Why are patients struggling to access life-saving immune globulin?Go to article: MimotopesGo to article: Deals in brief powered by GlobalDataGo to article: Nolato Company Insight Go to article: NolatoGo to article: The key list powered by GlobalDataGo to article: EventsGo to article: Next issue